Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics (MGNX) Q2 2022 Earnings Call Transcript
04:30am, Tuesday, 09'th Aug 2022 The Motley Fool
MGNX earnings call for the period ending June 30, 2022.
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2022 Results Earnings Call Transcript
11:05pm, Monday, 08'th Aug 2022
MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Chris James - VP, IR and Corporate Communications Scott Koenig - President and CEO Jim
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Monday, 08'th Aug 2022 Zacks Investment Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:00pm, Thursday, 04'th Aug 2022 Zacks Investment Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
09:55am, Friday, 29'th Jul 2022 Benzinga
Gainers
Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 20
LeMaitre Vascular (LMAT) Lags Q2 Earnings Estimates
09:55pm, Thursday, 28'th Jul 2022 Zacks Investment Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.38% and 2.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Is F45 Training Holdings Down By 56%? Here Are 28 Stocks Moving In Wednesday's Pre-Market Session
10:34am, Wednesday, 27'th Jul 2022 Benzinga
Gainers
Dave Inc. (NASDAQ: DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022.
Pzena Investment Mana
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
08:01pm, Monday, 25'th Jul 2022 GlobeNewswire Inc.
ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
04:01pm, Monday, 25'th Jul 2022
ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti
Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday
08:35am, Tuesday, 19'th Jul 2022 Benzinga
Gainers
AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share.
SKYX Platforms Corp. (NASDAQ: SKYX) jumped
Analysts Cuts Price Target On MacroGenics - Read Why
05:56pm, Tuesday, 12'th Jul 2022 Benzinga
BMO Capital Markets downgraded MacroGenics Inc (NASDAQ: MGNX) to Market Perform following the discontinuation of enoblituzumab (B7H3 antibody) for head and neck cancers.
The analyst said that e
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
02:21pm, Tuesday, 12'th Jul 2022 Benzinga
Upgrades
For Herbalife Nutrition Ltd (NYSE:HLF), Jefferies upgraded the previous rating of Hold to Buy. For the first quarter, Herbalife Nutrition had an EPS of $0.99, compared to year-ago quarter EPS
Why MacroGenics Stock Tumbled Today
04:28pm, Monday, 11'th Jul 2022 The Motley Fool
One of its phase 2 clinical trials was ended abruptly after several patients died.
